Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoTreme
2024-515660-31-00Phase 2Completed
- Sponsor
- Universitätsklinikum Schleswig-Holstein
- Start
- Oct 2024
- Modality
- Small Molecules, PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of durvalumab, tiragolumab, gemcitabine and cisplatin in intrahepatic cholangiocarcinoma (ICC), sponsored by Universitätsklinikum Schleswig-Holstein. Primary endpoint: R0/R1-resection rates. Started Oct 2024; status: completed.
02
Drugs
durvalumabtiragolumabgemcitabinecisplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on 2024-515660-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515660-31-00.